Dr. Jackson Orem

Executive Director

Uganda Cancer Institute

Dr. Jackson Orem is a medical oncologist and Executive Director of the Uganda Cancer Institute (UCI). UCI is a teaching and research institute of the Government of Uganda under the Ministry of Health affiliated with Makerere University and is spearheading all aspect of cancer research and training in oncology in Uganda.
UCI is designated as the oncology centre of excellence for East Africa which comprises six countries (Rwanda, Burundi, Kenya Tanzania, South Sudan and Uganda). Dr. Orem is leading the operationalization of the East Africa Centre of Excellence in Oncology (EACOE) at the Uganda Cancer Institute. The mandate of this is to provide specialized cancer care research and training for the entire East Africa region under the East African Community (EAC) network of Centers of Excellence (CoEs). J
He is also leading the development of several international collaborations with renowned international cancer centres and institutions for infrastructure, human resource capacity development. Such institutions include Fred Hutchinson Cancer Research Center, University of Washington, Case Western Reserve University, National Cancer Center of Korea (NCC) and lately University of Cambridge. Jackson is principal investigator in several NIH supported research projects through NIAID, AMC, ACTG and is recipient of a number of industry supported grants such as GSK funded Open Lab, MERCK, ROCHE.
Dr. Orem has strong international collaboration with civil society organizations such as American Cancer Society (ACS), and is the alternate chair for African Cancer Coalition an initiative with ACS and NCCN to harmonize cancer treatment guidelines for Sub-Saharan Africa. Jackson has strong working relationship with IAEA through their support to development of radiotherapy services for which he is the national lead (counterpart). Jackson is a member of the ASCO International affairs committee representing Africa, an active member of American Society of Hematology (ASH) and Society for Immunotherapy of Cancer (SITC).